238 related articles for article (PubMed ID: 30498897)
1. Safety and efficacy of targeted alpha therapy with
Królicki L; Bruchertseifer F; Kunikowska J; Koziara H; Królicki B; Jakuciński M; Pawlak D; Apostolidis C; Mirzadeh S; Rola R; Merlo A; Morgenstern A
Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):614-622. PubMed ID: 30498897
[TBL] [Abstract][Full Text] [Related]
2. Prolonged survival in secondary glioblastoma following local injection of targeted alpha therapy with
Krolicki L; Bruchertseifer F; Kunikowska J; Koziara H; Królicki B; Jakuciński M; Pawlak D; Apostolidis C; Mirzadeh S; Rola R; Merlo A; Morgenstern A
Eur J Nucl Med Mol Imaging; 2018 Jul; 45(9):1636-1644. PubMed ID: 29713762
[TBL] [Abstract][Full Text] [Related]
3. Dose escalation study of targeted alpha therapy with [
Królicki L; Bruchertseifer F; Kunikowska J; Koziara H; Pawlak D; Kuliński R; Rola R; Merlo A; Morgenstern A
Eur J Nucl Med Mol Imaging; 2021 Oct; 48(11):3595-3605. PubMed ID: 33860346
[TBL] [Abstract][Full Text] [Related]
4. Locoregional Treatment of Glioblastoma With Targeted α Therapy: [ 213 Bi]Bi-DOTA-Substance P Versus [ 225 Ac]Ac-DOTA-Substance P-Analysis of Influence Parameters.
Królicki L; Kunikowska J; Bruchertseifer F; Kuliński R; Pawlak D; Koziara H; Rola R; Morgenstern A; Merlo A
Clin Nucl Med; 2023 May; 48(5):387-392. PubMed ID: 36854309
[TBL] [Abstract][Full Text] [Related]
5. In vitro evaluation of
Majkowska-Pilip A; Rius M; Bruchertseifer F; Apostolidis C; Weis M; Bonelli M; Laurenza M; Królicki L; Morgenstern A
Chem Biol Drug Des; 2018 Jul; 92(1):1344-1356. PubMed ID: 29611298
[TBL] [Abstract][Full Text] [Related]
6.
Królicki L; Kunikowska J; Bruchertseifer F; Koziara H; Królicki B; Jakuciński M; Pawlak D; Rola R; Morgenstern A; Rosiak E; Merlo A
Semin Nucl Med; 2020 Mar; 50(2):141-151. PubMed ID: 32172799
[TBL] [Abstract][Full Text] [Related]
7. Alpha- versus beta-particle radiopeptide therapy in a human prostate cancer model (213Bi-DOTA-PESIN and 213Bi-AMBA versus 177Lu-DOTA-PESIN).
Wild D; Frischknecht M; Zhang H; Morgenstern A; Bruchertseifer F; Boisclair J; Provencher-Bolliger A; Reubi JC; Maecke HR
Cancer Res; 2011 Feb; 71(3):1009-18. PubMed ID: 21245097
[TBL] [Abstract][Full Text] [Related]
8. Towards Facile Radiolabeling and Preparation of Gallium-68-/Bismuth-213-DOTA-[Thi
Suthiram J; Ebenhan T; Marjanovic-Painter B; Sathekge MM; Zeevaart JR
Pharmaceutics; 2021 Aug; 13(9):. PubMed ID: 34575402
[TBL] [Abstract][Full Text] [Related]
9. Targeted alpha-radionuclide therapy of functionally critically located gliomas with 213Bi-DOTA-[Thi8,Met(O2)11]-substance P: a pilot trial.
Cordier D; Forrer F; Bruchertseifer F; Morgenstern A; Apostolidis C; Good S; Müller-Brand J; Mäcke H; Reubi JC; Merlo A
Eur J Nucl Med Mol Imaging; 2010 Jul; 37(7):1335-44. PubMed ID: 20157707
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic efficacy and toxicity of 225Ac-labelled vs. 213Bi-labelled tumour-homing peptides in a preclinical mouse model of peritoneal carcinomatosis.
Essler M; Gärtner FC; Neff F; Blechert B; Senekowitsch-Schmidtke R; Bruchertseifer F; Morgenstern A; Seidl C
Eur J Nucl Med Mol Imaging; 2012 Apr; 39(4):602-12. PubMed ID: 22237842
[TBL] [Abstract][Full Text] [Related]
11. Sequential cytarabine and alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia.
Rosenblat TL; McDevitt MR; Mulford DA; Pandit-Taskar N; Divgi CR; Panageas KS; Heaney ML; Chanel S; Morgenstern A; Sgouros G; Larson SM; Scheinberg DA; Jurcic JG
Clin Cancer Res; 2010 Nov; 16(21):5303-11. PubMed ID: 20858843
[TBL] [Abstract][Full Text] [Related]
12. Tachykinin Receptor-Selectivity of the Potential Glioblastoma-Targeted Therapy, DOTA-[Thi
Suthiram J; Pieters A; Mohamed Moosa Z; Zeevaart JR; Sathekge MM; Ebenhan T; Anderson RC; Newton CL
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768456
[TBL] [Abstract][Full Text] [Related]
13. Long-Term Tumor Control Following Targeted Alpha Therapy (TAT) of Low-Grade Gliomas (LGGs): A New Treatment Paradigm?
Krolicki L; Kunikowska J; Cordier D; Slavova N; Koziara H; Bruchertseifer F; Maecke HR; Morgenstern A; Merlo A
Int J Mol Sci; 2023 Oct; 24(21):. PubMed ID: 37958683
[TBL] [Abstract][Full Text] [Related]
14. Targeted alpha therapy of mCRPC: Dosimetry estimate of
Kratochwil C; Schmidt K; Afshar-Oromieh A; Bruchertseifer F; Rathke H; Morgenstern A; Haberkorn U; Giesel FL
Eur J Nucl Med Mol Imaging; 2018 Jan; 45(1):31-37. PubMed ID: 28891033
[TBL] [Abstract][Full Text] [Related]
15. Bismuth-213 and actinium-225 -- generator performance and evolving therapeutic applications of two generator-derived alpha-emitting radioisotopes.
Morgenstern A; Bruchertseifer F; Apostolidis C
Curr Radiopharm; 2012 Jul; 5(3):221-7. PubMed ID: 22642390
[TBL] [Abstract][Full Text] [Related]
16. Treatment of recurrent glioblastoma multiforme with GliaSite brachytherapy.
Chan TA; Weingart JD; Parisi M; Hughes MA; Olivi A; Borzillary S; Alahakone D; Detorie NA; Wharam MD; Kleinberg L
Int J Radiat Oncol Biol Phys; 2005 Jul; 62(4):1133-9. PubMed ID: 15990019
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of permanent iodine-125 seed implants and carmustine wafers in patients with recurrent glioblastoma multiforme.
Darakchiev BJ; Albright RE; Breneman JC; Warnick RE
J Neurosurg; 2008 Feb; 108(2):236-42. PubMed ID: 18240917
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of nitrogen-rich macrocyclic ligands for the chelation of therapeutic bismuth radioisotopes.
Wilson JJ; Ferrier M; Radchenko V; Maassen JR; Engle JW; Batista ER; Martin RL; Nortier FM; Fassbender ME; John KD; Birnbaum ER
Nucl Med Biol; 2015 May; 42(5):428-438. PubMed ID: 25684650
[TBL] [Abstract][Full Text] [Related]
19.
Sathekge M; Knoesen O; Meckel M; Modiselle M; Vorster M; Marx S
Eur J Nucl Med Mol Imaging; 2017 Jun; 44(6):1099-1100. PubMed ID: 28255795
[No Abstract] [Full Text] [Related]
20. Neoadjuvant targeting of glioblastoma multiforme with radiolabeled DOTAGA-substance P--results from a phase I study.
Cordier D; Forrer F; Kneifel S; Sailer M; Mariani L; Mäcke H; Müller-Brand J; Merlo A
J Neurooncol; 2010 Oct; 100(1):129-36. PubMed ID: 20217458
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
